Literature DB >> 14569006

Antiviral immune responses in gene-targeted mice expressing the immunoglobulin heavy chain of virus-neutralizing antibodies.

Lars Hangartner1, Beatrice M Senn, Birgit Ledermann, Ulrich Kalinke, Peter Seiler, Etienne Bucher, Raphaël M Zellweger, Katja Fink, Bernhard Odermatt, Kurt Bürki, Rolf M Zinkernagel, Hans Hengartner.   

Abstract

Two gene-targeted immunoglobulin heavy chain transgenic mouse strains, TgH(KL25) and TgH(VI10), expressing neutralizing specificities for lymphocytic choriomeningitis virus and vesicular stomatitis virus, respectively, have been generated. Three days after lymphocytic choriomeningitis virus infection, TgH(KL25) mice showed a thymus-independent neutralizing IgM response followed by thymus-dependent (TD) IgG. In contrast, WT mice mounted only a TD IgG response around day 80. These observations indicated that not only structural properties of the virus but also immunological parameters such as the frequency of B cells were indicative for the induction of thymus-independent versus TD Ig responses. Naïve vesicular stomatitis virusspecific Ig heavy chain transgenic mice displayed greatly elevated natural antibody titers. However, despite these high naïve titers, de novo activation of naïve CD4+ T and B cells was not blocked. Therefore, B cells giving rise to natural antibodies do not participate in virus-induced antibody responses.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14569006      PMCID: PMC240713          DOI: 10.1073/pnas.2135542100

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  47 in total

1.  Control of early viral and bacterial distribution and disease by natural antibodies.

Authors:  A F Ochsenbein; T Fehr; C Lutz; M Suter; F Brombacher; H Hengartner; R M Zinkernagel
Journal:  Science       Date:  1999-12-10       Impact factor: 47.728

2.  Correlation of T cell independence of antibody responses with antigen dose reaching secondary lymphoid organs: implications for splenectomized patients and vaccine design.

Authors:  A F Ochsenbein; D D Pinschewer; B Odermatt; A Ciurea; H Hengartner; R M Zinkernagel
Journal:  J Immunol       Date:  2000-06-15       Impact factor: 5.422

3.  Viral persistence in vivo through selection of neutralizing antibody-escape variants.

Authors:  A Ciurea; P Klenerman; L Hunziker; E Horvath; B M Senn; A F Ochsenbein; H Hengartner; R M Zinkernagel
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-14       Impact factor: 11.205

Review 4.  Marginal-zone B cells.

Authors:  Flavius Martin; John F Kearney
Journal:  Nat Rev Immunol       Date:  2002-05       Impact factor: 53.106

5.  Combinatorial immunoglobulin light chain variability creates sufficient B cell diversity to mount protective antibody responses against pathogen infections.

Authors:  Beatrice M Senn; Constantino López-Macías; Ulrich Kalinke; Alain Lamarre; Armando Isibasi; Rolf M Zinkernagel; Hans Hengartner
Journal:  Eur J Immunol       Date:  2003-04       Impact factor: 5.532

6.  Requirement for theta-bearing cells in lymphocytic choriomeningitis virus-induced central nervous system disease.

Authors:  G A Cole; N Nathanson; R A Prendergast
Journal:  Nature       Date:  1972-08-11       Impact factor: 49.962

7.  Determination of total and merecaptothanol-resistant antibody in the same serum sample.

Authors:  D W Scott; R K Gershon
Journal:  Clin Exp Immunol       Date:  1970-02       Impact factor: 4.330

8.  B-1 and B-2 cell-derived immunoglobulin M antibodies are nonredundant components of the protective response to influenza virus infection.

Authors:  N Baumgarth; O C Herman; G C Jager; L E Brown; L A Herzenberg; J Chen
Journal:  J Exp Med       Date:  2000-07-17       Impact factor: 14.307

9.  B cell receptor-independent stimuli trigger immunoglobulin (Ig) class switch recombination and production of IgG autoantibodies by anergic self-reactive B cells.

Authors:  Tri Giang Phan; Michelle Amesbury; Sandra Gardam; Jeffrey Crosbie; Jhagvaral Hasbold; Philip D Hodgkin; Antony Basten; Robert Brink
Journal:  J Exp Med       Date:  2003-03-31       Impact factor: 14.307

10.  Hyper immunoglobulin E response in mice with monoclonal populations of B and T lymphocytes.

Authors:  M A Curotto de Lafaille; S Muriglan; M J Sunshine; Y Lei; N Kutchukhidze; G C Furtado; A K Wensky; D Olivares-Villagómez; J J Lafaille
Journal:  J Exp Med       Date:  2001-11-05       Impact factor: 14.307

View more
  27 in total

Review 1.  Immunological memory ≠ protective immunity.

Authors:  Rolf M Zinkernagel
Journal:  Cell Mol Life Sci       Date:  2012-04-06       Impact factor: 9.261

2.  Bisphosphonates target B cells to enhance humoral immune responses.

Authors:  Elena Tonti; Nereida Jiménez de Oya; Gabriele Galliverti; E Ashley Moseman; Pietro Di Lucia; Angelo Amabile; Stefano Sammicheli; Marco De Giovanni; Laura Sironi; Nicolas Chevrier; Giovanni Sitia; Luigi Gennari; Luca G Guidotti; Ulrich H von Andrian; Matteo Iannacone
Journal:  Cell Rep       Date:  2013-10-10       Impact factor: 9.423

3.  Low-affinity B cells transport viral particles from the lung to the spleen to initiate antibody responses.

Authors:  Juliana Bessa; Franziska Zabel; Alexander Link; Andrea Jegerlehner; Heather J Hinton; Nicole Schmitz; Monika Bauer; Thomas M Kündig; Philippe Saudan; Martin F Bachmann
Journal:  Proc Natl Acad Sci U S A       Date:  2012-11-20       Impact factor: 11.205

Review 4.  Interactions of viruses and the humoral innate immune response.

Authors:  Bailey E Maloney; Krishani Dinali Perera; Danielle R D Saunders; Naemi Shadipeni; Sherry D Fleming
Journal:  Clin Immunol       Date:  2020-02-04       Impact factor: 3.969

5.  Type I interferon suppresses virus-specific B cell responses by modulating CD8+ T cell differentiation.

Authors:  E Ashley Moseman; Tuoqi Wu; Juan Carlos de la Torre; Pamela L Schwartzberg; Dorian B McGavern
Journal:  Sci Immunol       Date:  2016-10-21

6.  Type I interferon suppresses de novo virus-specific CD4 Th1 immunity during an established persistent viral infection.

Authors:  Ivan Osokine; Laura M Snell; Cameron R Cunningham; Douglas H Yamada; Elizabeth B Wilson; Heidi J Elsaesser; Juan Carlos de la Torre; David Brooks
Journal:  Proc Natl Acad Sci U S A       Date:  2014-05-05       Impact factor: 11.205

7.  The VP6 protein of rotavirus interacts with a large fraction of human naive B cells via surface immunoglobulins.

Authors:  Nathalie Parez; Antoine Garbarg-Chenon; Cynthia Fourgeux; Françoise Le Deist; Annabelle Servant-Delmas; Annie Charpilienne; Jean Cohen; Isabelle Schwartz-Cornil
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

Review 8.  Neutralizing antibodies in hepatitis C virus infection.

Authors:  Mirjam-B Zeisel; Samira Fafi-Kremer; Isabel Fofana; Heidi Barth; Francoise Stoll-Keller; Michel Doffoel; Thomas-F Baumert
Journal:  World J Gastroenterol       Date:  2007-09-28       Impact factor: 5.742

9.  Immune requirements of post-exposure immunization with modified vaccinia Ankara of lethally infected mice.

Authors:  Henning Lauterbach; Ronny Kassub; Juliane Pätzold; Jana Körner; Michael Brückel; Admar Verschoor; Paul Chaplin; Mark Suter; Hubertus Hochrein
Journal:  PLoS One       Date:  2010-03-11       Impact factor: 3.240

10.  Kinetics of protective antibodies are determined by the viral surface antigen.

Authors:  Daniel D Pinschewer; Mar Perez; Eswaraka Jeetendra; Thomas Bächi; Edit Horvath; Hans Hengartner; Michael A Whitt; Juan Carlos de la Torre; Rolf M Zinkernagel
Journal:  J Clin Invest       Date:  2004-10       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.